Cargando…
Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
Although the ubiquitous human herpesviruses (HHVs) are rarely associated with serious disease of the healthy host, primary infection and reactivation in immunocompromised individuals can lead to significant morbidity and, in some cases, mortality. Effective drugs are available for clinical treatment...
Autores principales: | Groves, Ian J., Sinclair, John H., Wills, Mark R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343845/ https://www.ncbi.nlm.nih.gov/pubmed/32714883 http://dx.doi.org/10.3389/fcimb.2020.00329 |
Ejemplares similares
-
Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019) -
Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections
por: Asha, Kumari, et al.
Publicado: (2021) -
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023) -
Evasion of Intracellular DNA Sensing by Human Herpesviruses
por: Bhowmik, Debipreeta, et al.
Publicado: (2021) -
The Role of Lytic Infection for Lymphomagenesis of Human γ-Herpesviruses
por: Münz, Christian
Publicado: (2021)